News
Harlan and Fluofarma Sign Strategic Collaboration Agreement
Harlan Contract Research Services a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a contract research organization specializing in high content analysis, have announced a strategic partnership that will strengthen the companies’ drug discovery and translational medicine services.
Through the alliance, Harlan CRS will utilize Fluofarma’s expertise in high content analysis, biomarkers quantification and high content histology, including applications to mechanistic toxicology and prediction of toxicity.
“One of our goals is to help our customers reduce the risk of drug attrition during the development process,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “This alliance with Fluofarma enables us to strengthen our services during the early stages of development so that we can be a key partner for our customers.”
“We’re very proud of this agreement with Harlan CRS,” added Jean-Baptiste Pin, CEO of Fluofarma. “It will be a tremendous growth accelerator for Fluofarma by improving our international visibility. For us, it’s the confirmation that our high content analysis technologies and translational research skills can add value to the global drug development process.”
About Harlan Contract Research Services
Harlan Contract Research Services (CRS), a division of Harlan Laboratories, Inc., is a privately held provider of general and specialty toxicology services to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan CRS’ focus is on providing customers with services to optimize product development. For more information, please visit www.harlan.com/crs.
About Fluofarma
Fluofarma is privately held contract research organization performing and developing cell- and tissue-based assays for preclinical and clinical drug discovery by using High-Content Analysis (HCA) technologies. Based in France, Fluofarma specializes in complex drug discovery studies and proposes translational services for every step of the drug development process. In addition to its routine assays, Fluofarma develops HCA assays and models on demand. For more information, visit www.fluofarma.com.
###